Scribd
Upload
22 views1 page

Pharmaceuticals Infographic May 2024

pharma value chain analysis

Uploaded by

uhi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
22 views1 page

Pharmaceuticals Infographic May 2024

pharma value chain analysis

Uploaded by

uhi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 1

May 2024

PHARMACEUTICALS

Indian Pharmaceutical Market (US$ billion)

450.0

MARKET 130.0
42.0 49.78 65.0
SIZE
2021 2023 2024P 2030P 2047P
Note: P-Projected

R&D Investment by Indian Pharma Companies* (% of sales)


8.7 8.5 8.6 8.4
7.9
7.2

SECTOR
COMPOSITION FY16 FY17 FY18 FY19 FY20 FY21

Note: *Top 10 companies as per research by HDFC Securities

Pharmaceutical Export from India (US$ billion) Government Expenditure on Health in India
(US$ billion)
27.8
24.6 25.4 FY17
22.4
19.1 20.7 66.4 FY18
16.9 16.8 17.3 35.1
64.7 FY19
34.9
FY20
KEY 38.6 41.4 FY21
46.0
TRENDS FY22
FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY23
Note: Till FY24 Note: E-Estimate

Pradhan Mantri Bhartiya


GOVERNMENT Janaushadhi Pariyojana COVID BEEP National Health Policy
(PMBJP)
INITIATIVES
• Cost Efficiency: India has emerged as the medial tourism hub of the world providing cost-effective treatments with the latest technology enabled
by several pathbreaking reforms and provisions in healthcare sector. Access to affordable HIV treatment from India is one of the greatest success
stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world, thereby rightly making it the ‘Pharmacy of the World’.
• Economic Drivers: The total market size of the Indian Pharma Industry is expected to reach US$ 130 billion by 2030 and US$ 450 billion market by
2047. The domestic pharmaceutical industry would likely reach US$ 57 billion by FY25 and see an increase in operating margins of 100-150 basis
points (bps). India has the largest number of USFDA-compliant pharmaceutical plants outside the US and over 2,000 WHO-GMP approved facilities,
serving demand from 150+ countries worldwide, with 10,500+ manufacturing facilities
• Policy support: The PLI scheme for pharmaceuticals is being implemented with a total outlay of the Rs. 15,000 crore (US$ 2.04 billion) spanning
from 2020-21 to 2028-29, to boost India's manufacturing capacity, elevate investment, and diversify product offerings in the sector. Through
Pradhan Mantri Bhartiya Jan Aushadhi Kendras (PMBJKs) government has set a target to increase the number of PMBJKs to 10,500 by the end of
ADVANTAGE March 2025. Product basket of PMBJP comprises of 1,451 drugs and 240 surgical instruments. The Union Cabinet, on April 26, 2023, approved the
National Medical Devices Policy, 2023. The National Medical Devices Policy, 2023 is expected to facilitate an orderly growth of the medical device
sector to meet the public health objectives of access, affordability, quality and innovation.
INDIA • Increasing Investments: The cumulative FDI equity inflow in the Drugs and Pharmaceuticals industry is US$ 22.52 billion during the period April
2000-March 2024, almost 3.4% of the total inflow received across sectors. In the Interim Budget 2024-25, the government earmarked Rs 1,000
crore (US$ 120 million) for the promotion of bulk drug parks for FY25, a significant increase from the previous year.
Copyright © 2024 IBEF. All rights reserved. www.ibef.org

You might also like